Inari Medical (NARI)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Inari Medical (NARI)
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes; ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism, InThrill system to treat small vessel thrombosis, LimFlow system and others. Geographically, the company generates majority of its revenue from United States and rest from International markets.
Key Insights
Critical company metrics and information
Share Price
$51.08Market Cap
$2.99 BillionTotal Outstanding Shares
58.54 Million SharesTotal Employees
1,300Dividend
No dividendIPO Date
May 22, 2020SIC Description
Surgical & Medical Instruments & ApparatusHomepage
https://www.inarimedical.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
July 1, 2023 to June 30, 2024
Metric | Value |
---|---|
Net Cash Flow, Continuing | $12.23 Million |
Net Cash Flow | $12.36 Million |
Net Cash Flow From Operating Activities | $27.41 Million |
Exchange Gains/Losses | $125000.00 |
Net Cash Flow From Financing Activities | $681000.00 |
Net Cash Flow From Investing Activities | $-14.49 Million |
Net Cash Flow From Financing Activities, Continuing | $681000.00 |
Net Cash Flow From Investing Activities, Continuing | $-14.49 Million |
Net Cash Flow From Operating Activities, Continuing | $27.41 Million |
Income Statement
July 1, 2023 to June 30, 2024
Metric | Value |
---|---|
Income/Loss From Continuing Operations Before Tax | $-35.09 Million |
Costs And Expenses | $582.57 Million |
Net Income/Loss Attributable To Parent | $-57.05 Million |
Basic Average Shares | $115.72 Million |
Benefits Costs and Expenses | $582.57 Million |
Operating Income/Loss | $-46.80 Million |
Diluted Earnings Per Share | $0.99 |
Selling, General, and Administrative Expenses | $406.99 Million |
Net Income/Loss | $-57.05 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Gross Profit | $477.11 Million |
Basic Earnings Per Share | $0.98 |
Income/Loss From Continuing Operations After Tax | $-57.05 Million |
Diluted Average Shares | $114.90 Million |
Cost Of Revenue | $70.37 Million |
Income Tax Expense/Benefit | $21.96 Million |
Revenues | $547.47 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Research and Development | $96.17 Million |
Operating Expenses | $523.91 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-57.05 Million |
Balance Sheet
July 1, 2023 to June 30, 2024
Metric | Value |
---|---|
Other Current Assets | $199.99 Million |
Fixed Assets | $23.00 Million |
Current Liabilities | $138.26 Million |
Wages | $54.36 Million |
Liabilities | $249.12 Million |
Accounts Payable | $16.38 Million |
Equity | $423.81 Million |
Assets | $672.93 Million |
Noncurrent Assets | $423.58 Million |
Intangible Assets | $143.11 Million |
Inventory | $49.36 Million |
Equity Attributable To Parent | $423.81 Million |
Current Assets | $249.35 Million |
Liabilities And Equity | $672.93 Million |
Noncurrent Liabilities | $110.86 Million |
Other Non-current Assets | $257.47 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Other Current Liabilities | $67.52 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.